Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck

Landis, Sarah H.; El‐Hariry, Iman; Herk‐Sukel, Myrthe P. P. van; Haak, Pieter van den; Janssen‐Heijnen, M.L.G.; Beest, Fernie J. A. Penning-van; Herings, Ron M. C.

doi:10.1002/hed.21720

Cited by 31 publications

(33 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The data presented herein further support results from our previous studies in UADT malignancies regarding an association between metformin use and improved survival outcomes . It is important to note that, although the prevalence of diabetes in the HNSCC population at large is estimated to be <10%, our cohort presented with 20% of patients carrying a diagnosis of diabetes mellitus at the time of cancer treatment …”

Section: Discussionsupporting

confidence: 88%

Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 88%

Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma

et al. 2014

View full text Add to dashboard Cite

show abstract

“…28 The consequent barriers to health care access experienced in this population may explain the higher prevalence of severe comorbidity and multiple different conditions observed in our population compared to others. 4, 5, 7 ,…”

Section: Discussionmentioning

confidence: 99%

“…A number of studies have demonstrated the increased prevalence of comorbidity in head and neck cancer patients, 2, 4, 5 which can impact treatment selection 6, 7 and prognosis. 8–13 For example, patients with severe cardiovascular or respiratory comorbidity may be excluded from surgical treatment because of an increased potential for adverse treatment outcomes.…”

Section: Introductionmentioning

confidence: 99%

Comorbidity, human papillomavirus infection and head and neck cancer survival in an ethnically diverse population

et al. 2013

View full text Add to dashboard Cite

Objective To demonstrate the importance of comorbid conditions in head and neck squamous cell carcinoma (HNSCC), we assessed the association between comorbidity and survival in an inner-city population of HNSCC patients. Patients and Methods Comorbid status at diagnosis was derived using medical records and the Adult Comorbidity Evaluation-27 (ACE-27) index on 288 patients with histologically confirmed HNSCC from Montefiore Medical Center in the Bronx (NY) between 2002 and 2011. The association between comorbidity, tumor human papillomavirus (HPV) status and overall and disease specific survival was assessed by Kaplan-Meier analysis and multivariable Cox regression adjusting for clinico-pathologic factors. Results The study population consisted of primary oropharyngeal (36%), laryngeal (33%) and oral cavity cancer patients (31%). Overall, 19% had no comorbidity, 43% mild comorbidity, 29% moderate comorbidity, and 9% severe comorbidity. The most common comorbid conditions were hypertension, diabetes mellitus, respiratory disease, other malignancies, and illicit drug use. Survival analyses revealed that increased comorbidity at diagnosis was significantly related to poorer overall survival (p=0.016), but not to cancer survival (p=0.369) or recurrence (p=0.652). Oropharyngeal cancer patients with HPV DNA positive tumors and lower levels of comorbidity had significantly better overall survival compared to patients with HPV negative tumors (hazard ratio = 0.2, 95%CI: 0.04–0.8), however there was no significant difference in overall (or disease specific) survival by HPV status among patients with higher levels of comorbidity at diagnosis (hazard ratio = 0.7, 95%CI: 0.2–2.8). Conclusion In an inner-city predominantly minority population, comorbidity at HNSCC diagnosis is relatively common and associated with poor overall survival, but not cancer survival or recurrence. Interestingly, the relationship between HPV and improved survival appears to be specific to patients with low comorbidity at diagnosis.

show abstract

“…Our study showed that the presence of two or more patient comorbidities was a significant risk factor for NCM. This may reflect the fact that the HNC patients have a higher prevalence of comorbidities than the general population (Landis et al., ) and that cancer patients with severe comorbidities have a higher incidence of complications and mortality secondary to cancer treatment (Derks, de Leeuw & Hordijk, ; Ferrier, Spuesens, Le Cessie & Baatenburg de Jong, ). Indeed, the cancer treatment itself may increase the risk of comorbidities even after 1 year of treatment, particularly in patients undergoing chemotherapy (Montero‐Miranda & Ganly, ).…”

Section: Discussionmentioning

confidence: 99%

Risk factors for competing non‐cancer mortality after definitive treatment for advanced‐stage head and neck cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck

Abstract: High rates of acute and chronic comorbidity were observed; knowledge of comorbidity burden aids in establishing a benefit-risk profile for investigational SCCHN therapies.

Cited by 31 publications

References 32 publications

Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma

Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma

Comorbidity, human papillomavirus infection and head and neck cancer survival in an ethnically diverse population

Risk factors for competing non‐cancer mortality after definitive treatment for advanced‐stage head and neck cancer

Contact Info

Product

Resources

About